Bortenat 2mg Injection

Bortenat 2mg Injection contains Bortezomib, a potent proteasome inhibitor widely used in the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib works by blocking the proteasome pathway, which is crucial for protein degradation in cells. This inhibition leads to the accumulation of damaged proteins, triggering cancer cell death and slowing the growth of tumors.

Key Features:

• Contains Bortezomib, a proven chemotherapy agent
• Indicated for the treatment of multiple myeloma and mantle cell lymphoma
• Works by inhibiting proteasomes to induce cancer cell death
• Administered via injection for direct therapeutic effects
• Often used as part of a combination therapy for enhanced effectiveness